Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer

30 Oct 2021

Abstract excerpt

Cyclin-dependent kinase 9 (CDK9) activity is correlated with worse outcomes of triple-negative breast cancer (TNBC) patients. The heterodimer between CDK9 with cyclin T1 is essential for maintaining the active state of the kinase and targeting this protein–protein interaction (PPI) may offer promising avenues for selective CDK9 inhibition. Herein, we designed and generated a library of metal complexes bearing the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35530158
DOI: 10.1016/j.apsb.2021.10.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancerPMID 35530158Read ↗

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting CDK9 for Anti-Cancer TherapeuticsSemantic proximity Read ↗

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug TargetSemantic proximity Read ↗

Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells.Semantic proximity Read ↗

Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biologySemantic proximity Read ↗

Research and Development of a Multi-Target HER2 Inhibitor (CPD 1) and Its Mechanism and Application in Combating HER2-Positive Breast CancerSemantic proximity Read ↗

Progress of Metal‐Based Anticancer Chemotherapeutic Agents in Last two Decades and their Comprehensive Biological (DNA/RNA Binding, Cleavage and Cytotoxicity Activity) StudiesSemantic proximity Read ↗

Exploring Anticancer and Antituberculosis Activities of Pt(II) Quinazoline Complexes Derived from EMNEDAQZHO ((E)-2-methyl-3-(1-(naphthalen-1-yl)ethylideneamino)quinazolin-4(3H)-one): Insights and ApplicationsSemantic proximity Read ↗

<i>In silico </i>analysis of multiple targets (HER2 receptor and DNA) inhibition by natural isoquinoline derivatives for breast cancer treatmentSemantic proximity Read ↗

Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-4H-[1,2,3]triazolo[4,5-c]quinolin-4-one (CQ211) as a Highly Potent and Selective RIOK2 InhibitorSemantic proximity Read ↗

Triorganotin complexes in cancer chemotherapy: Mechanistic insights and future perspectivesSemantic proximity Read ↗

Next generation protein-corrole bio-assemblies provide effective tumoricidal treatment in a metastatic triple-negative breast cancer modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.